Clinical Trial

RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients

Name: RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients — clinical trial record (NCT07056478)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.

Trial Details

NCT Number	NCT07056478
Lead Sponsor	Prince of Wales Hospital, Shatin, Hong Kong
Conditions	Sarcopenia in Elderly
Enrollment	130 participants
Start Date	2026-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2030-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-09